Stockscreener 앱 받기
124.43
1.72%
-2.18
시간 외 거래:
124.83
0.40
+0.32%
전일 마감가:
$126.61
열려 있는:
$126.18
하루 거래량:
5.14M
Relative Volume:
0.89
시가총액:
$216.57B
수익:
$43.84B
순이익/손실:
$13.94B
주가수익비율:
15.56
EPS:
7.9979
순현금흐름:
$6.78B
1주 성능:
-2.75%
1개월 성능:
-6.52%
6개월 성능:
-4.65%
1년 성능:
+9.73%
1일 변동 폭
$124.12
$126.55
1주일 범위
$124.12
$128.77
52주 변동 폭
$110.86
$140.84
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
ABT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
124.43 | 220.36B | 43.84B | 13.94B | 6.78B | 7.9979 |
|
BSX
Boston Scientific Corp
|
100.30 | 149.61B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
369.59 | 143.72B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
91.73 | 119.58B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
82.69 | 48.25B | 5.69B | 1.41B | 577.90M | 6.9828 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Barclays Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $162 - 富途牛牛
Abbott Laboratories (ABT): Evaluating Its Valuation Following Recent Share Price Pullback - simplywall.st
How Abbott Laboratories stock reacts to inflationary pressuresWeekly Risk Report & AI Forecasted Stock Moves - Fundação Cultural do Pará
Data supports Abbott Tendyne mitral valve replacement - MassDevice
Billionaire Israel "Izzy" Englander Has Loaded Up on This Dividend King. Should You? - The Motley Fool
Is Abbott Laboratories stock a good choice for value investors2025 Geopolitical Influence & AI Forecasted Stock Moves - Fundação Cultural do Pará
Technical signs of recovery in Abbott LaboratoriesMarket Volume Summary & Target Return Focused Stock Picks - newser.com
What makes Abbott Laboratories stock attractive to growth fundsM&A Rumor & Risk Adjusted Buy and Sell Alerts - Fundação Cultural do Pará
Will Abbott Laboratories (ABL) stock maintain strong growth2025 Market Overview & Community Consensus Stock Picks - newser.com
Abbott Laboratories, facing hundreds of lawsuits over safety of formula for premature babies, notches a win in federal court - Slipcase
Abbott’s New Study on Dydrogesterone: A Potential Game-Changer for Endometriosis Pain - TipRanks
Is Abbott Laboratories (Common Stock) (ABL0) stock a buy for dividend portfoliosJuly 2025 Price Swings & Precise Buy Zone Identification - Fundação Cultural do Pará
Abbott Laboratories wins Illinois court case on NEC baby formula claims - Global Food Industry News
Using R and stats models for Abbott Laboratories forecastingWeekly Market Summary & Real-Time Volume Triggers - newser.com
What is the fair value estimate for Abbott Laboratories (ABL) stock in 2025Trade Risk Report & Smart Swing Trading Techniques - newser.com
Will a bounce in Abbott Laboratories offer an exitSwing Trade & High Conviction Investment Ideas - newser.com
Is Abbott Laboratories stock a buy in volatile marketsGap Up & Verified Stock Trade Ideas - newser.com
Abbott Laboratories (ABT) Surged Ahead of the Market in 2025 with Steady Earnings Momentum - MSN
Abbott Laboratories wins lawsuit over safety of baby formula - Chicago Tribune
Abbott Wins Third Bellwether as Judge Rules Human-Milk Alternative ‘Unfeasible’ - USA Herald
Abbott Wins Third Bellwether In Cow Milk Baby Formula MDL - Law360
Abbott wins third of four 'bellwether' infant formula lawsuits - Crain's Chicago Business
Protein Bar Market Size, Share, and Growth 2025-2035 | Abbott - openPR.com
Abbott Can't Expand Glucose Monitor Sales Ban At UPC - Law360
Abbott Laboratories (ABT): Exploring Valuation After a Recent Share Price Pullback - Yahoo Finance
Meet RFK’s Corporate Underlings - The American Prospect
Is Abbott Laboratories stock dividend growth reliableJuly 2025 Catalysts & Smart Swing Trading Alerts - newser.com
How Abbott’s Innovative Partnerships Are Shaping Its 2025 Valuation Amid 12.8% YTD Gain - simplywall.st
United States Chronic Obstructive Pulmonary Disease Market Report 2025-2033, Profiles of AstraZeneca, Pfizer, GSK, Novartis, Astellas Pharma, Abbott Laboratories, Boehringer Ingelheim, Almirall - GlobeNewswire
1 Safe-and-Steady Stock with Exciting Potential and 2 We Question - The Globe and Mail
Synlait Milk Confirms Investment Regulator's Approval for Abbott's Acquisition of North Island Assets - MarketScreener
A Look Into Abbott Laboratories Inc's Price Over Earnings - Sahm
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock - Yahoo Finance
The 5 Most Interesting Analyst Questions From Abbott Laboratories’s Q3 Earnings Call - Yahoo Finance
How Abbott Laboratories stock compares to growth peersMarket Movement Recap & Free Weekly Watchlist of Top Performers - newser.com
Can Abbott Laboratories (Common Stock) (ABL0) stock sustain margin levelsGap Down & Entry and Exit Point Strategies - newser.com
Is Abbott Laboratories (ABL) stock cheap by valuation metricsTake Profit & Risk Adjusted Buy/Sell Alerts - newser.com
Is Abbott Laboratories showing signs of accumulationMarket Movement Recap & Expert Approved Momentum Ideas - newser.com
Volatility clustering patterns for Abbott LaboratoriesPortfolio Risk Report & Real-Time Market Trend Scan - newser.com
Walmart to sell Abbott's CGM in US 1st - Fierce Biotech
Abbott - Boston Athletic Association
Daiwa Securities Adjusts Abbott Laboratories Price Target to $136 From $134, Maintains Outperform Rating - MarketScreener
Walmart to be first US retailer to sell Abbott's continuous glucose monitor - Reuters
Walmart (WMT) Expands Health Offerings with Abbott's Lingo Gluco - GuruFocus
Functional Foods Forecast and Company Analysis Report 2025: A $678.32 Billion Market by 2033 Featuring Abbott, Amway, BASF, Cargill, Clif Ba, Danone, General Mills, Kellogg, Kerry, Nestle - Yahoo Finance
Walmart said to become first physical retailer to sell Abbott’s OTC glucose monitor, Lingo - Seeking Alpha
Walmart to be first US retailer to sell Abbott's continuous glucose monitor, Axios reports - TradingView
How to read the order book for Abbott Laboratories2025 Earnings Surprises & Trade Opportunity Analysis Reports - newser.com
Abbott Laboratories (ABT) Rated Buy as Benchmark Highlights Diagnostics Growth and Global Resilience - Insider Monkey
Bringing Biomarkers to the Bedside: The Clinical Promise of Abbott’s TBI Test - NeurologyLive
Did Mixed Segment Results and Narrowed Guidance Just Shift Abbott Laboratories' (ABT) Investment Narrative? - Yahoo Finance
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.66%
0.61%
자본화:
|
볼륨(24시간):